spironolactone + adalimumab + infliximab + ertapenem + finasteride + triamcinolone + oral antibiotics + birth control

This combination refers to a set of core therapies utilized in the management of **Hidradenitis Suppurativa (HS)**, as identified in clinical research evaluating the impact of Polycystic Ovary Syndrome (PCOS) on HS severity. The regimen includes anti-androgens (**spironolactone**, **finasteride**), biologic TNF-alpha inhibitors (**adalimumab**, **infliximab**), corticosteroids (**triamcinolone**), and various antimicrobial agents (**ertapenem**, **oral antibiotics**), alongside hormonal **birth control**. These treatments aim to address the inflammatory, hormonal, and bacterial components of HS pathogenesis. Adalimumab is currently the only FDA-approved biologic for HS, while the other components are frequently used off-label or as standard-of-care supportive therapies.